Alexander Drtil, MD
Clinical Cardiac Electrophysiology · Houston, TXNPI 1942294715
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $81,066 of the $125,883 with a category attached, or 64.4%. Abbott accounts for 71.9% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $40,945 and has fallen 85.9% since, to $5,784 in 2025.
Across 574 payments — averaging $219.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$91K
- Johnson & Johnson$28K
- Medtronic$3K
- Biosense Webster, Inc.$2K
- Boston Scientific$912
- E.r. Squibb & Sons, L.L.C.$431
- plus $1K from 12 others
Across 59 payments — averaging $606.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$24K
- Biotronik Inc.$12K
What the payments were for
- Consulting fees$81,06664%
- Speaking & faculty fees$29,78124%
- Travel & lodging$3,7113%
- Food & beverage$11,3139%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 285 | $90,540 |
| Johnson & Johnson | 66 | $28,118 |
| Medtronic(2 entities) | 73 | $3,216 |
| Biosense Webster, Inc. | 49 | $1,631 |
| Boston Scientific | 32 | $912 |
| E.r. Squibb & Sons, L.L.C. | 25 | $431 |
| Sanofi-aventis U.S. LLC | 14 | $270 |
| Biotronik Inc. | 8 | $243 |
| Cardiva Medical, Inc. | 6 | $201 |
| Altathera Pharmaceuticals LLC | 4 | $84 |
| Novartis | 3 | $57 |
| Amarin Pharma, Inc. | 2 | $45 |
| Irhythm Technologies, Inc. | 2 | $40 |
| Novo Nordisk | 1 | $23 |
| Preventice Services, LLC | 1 | $22 |
| Elutia, Inc. | 1 | $19 |
| Pfizer | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$27,166
- Accent Pacemaker$17,370
- ACCENT$16,680
- EnSite Precision Cardiac Mapping System$11,662
- GALLANT$11,509
- Allure Quadra RF CRT Pacemaker$7,245
- Quadra Assura CRT Defibrillator$5,450
- Fortify Assura, Ellipse ICD$4,375
- Assurity Pacemaker$3,600
- Ensite Cardiac Mapping System$2,072
- EP-WorkMate Claris System$2,000
- Quadra Allure MP RF CRT Pacemkr$1,775
- Micra$1,591
- AVEIR$1,563
- Allure CRT Pacemaker$728
- AMPLATZER Occluders$538
- ALLURE$495
- Confirm Rx$348
- AMPLATZER TorqVue Delivery Systm$170
- ViewMate Intracardiac Echo$159
How this compares
$125,883 in reported general payments places this provider in the 85th percentile of 233 clinical cardiac electrophysiology providers in Texas.
See all clinical cardiac electrophysiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 653 | $585,214 |
| XareltoRivaroxaban | 311 | $324,741 |
| MultaqDronedarone Hcl | 90 | $130,421 |
| Flecainide Acetate | 478 | $20,523 |
| Propafenone Hcl ErPropafenone Hcl | 53 | $9,598 |
| Amiodarone Hcl | 574 | $8,939 |
| EntrestoSacubitril/Valsartan | 11 | $7,192 |
| Metoprolol Succinate | 283 | $4,626 |
| Digoxin | 44 | $912 |
| Metoprolol Tartrate | 114 | $846 |
| SotalolSotalol Hcl | 23 | $843 |
| Minocycline Hcl | 98 | $616 |
| Carvedilol | 68 | $458 |
| Diltiazem 24hr Er (Xr)Diltiazem Hcl | 11 | $400 |
| Sucralfate | 44 | $309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $17 | $585,214653 claims |
| Johnson & JohnsonXarelto | $28,118 | $324,741311 claims |
| Sanofi-aventis U.S. LLCMultaq | $270 | $130,42190 claims |
| NovartisEntresto | $57 | $7,19211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 233 clinical cardiac electrophysiology providers in Texas.
Other clinical cardiac electrophysiology in Houston
- Miguel ValderrabanoHouston$461K
- Mehdi RazaviHouston$358K
- Ilyas ColombowalaHouston$204K
- Ramesh HariharanHouston$165K
- Nadim NasirHouston$162K
- John SegerHouston$147K
- Hamid Afshar-KharaghanHouston$112K
- David BurklandHouston$101K
- Jie ChengHouston$82K
- Paul SchurmannHouston$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.